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Background: Although increasing attention is being paid to knowledge translation (KT), research findings are not
being utilized to the desired extent. The present study explores the role of evidence, barriers, and factors facilitating
the uptake of evidence in the change in malaria treatment policy in Uganda, building on previous work in Uganda
that led to the development of a middle range theory (MRT) outlining the main facilitatory factors for KT.
Application of the MRT to a health policy case will contribute to refining it.
Methods: Using a case study approach and mixed methods, perceptions of respondents on whether evidence was
available, had been considered and barriers and facilitatory factors to the uptake of evidence were explored. In
addition, the respondents’ rating of the degree of consistency between the policy decision and available evidence
was assessed. Data collection methods included key informant interviews and document review. Qualitative data
were analysed using content thematic analysis, whereas quantitative data were analysed using Excel spreadsheets.
The two data sets were eventually triangulated.
Results: Evidence was used to change the malaria treatment policy, though the consistency between evidence and
policy decisions varied along the policy development cycle. The availability of high-quality and contextualized
evidence, including effective dissemination, Ministry of Health institutional capacity to lead the KT process, intervention
of the WHO and a regional professional network, the existence of partnerships for KT with mutual trust and availability
of funding, tools, and inputs to implement evidence, were the most important facilitatory factors that enhanced the
uptake of evidence. Among the barriers that had to be overcome were resistance from implementers, the health
system capacity to implement evidence, and financial sustainability.
Conclusion: The results agree with facilitatory factors identified in the earlier developed MRT, though additional
factors emerged. These results refine the earlier MRT stating that high-quality and contextualized evidence will
be taken up in policies, leading to evidence-informed policies when the MoH leads the KT process, partnerships
are in place for KT, the WHO and regional professional bodies play a role, and funding, tools, and required inputs
for implementing evidence are available.
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Although commitment to knowledge translation (KT)
has been an issue of interest to funders of research, re-
searchers, and policymakers, there is a concern that re-
search findings are not being utilized to the extent that
they should [1-4]. Several studies have documented the
barriers and facilitatory factors for the uptake of evidence* Correspondence: julienabyonga@yahoo.com
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article, unless otherwise stated.in policy development and many lessons have been
learned [5-9]. Delays in using evidence to change treat-
ment protocols, which in some instances have been longer
than seven years [7], have led to wasting resources due to
the continued use of ineffective care, with suboptimal
health outcomes. Among the documented reasons for
such delays is the poor quality of available evidence, polit-
ical processes lacking inclusive dialogue, donor influences,
a lack of openness to using evidence by policy makers,
lack of required inputs to implement the evidence, limited
alternatives, and concerns regarding the duration overd Central Ltd. This is an Open Access article distributed under the terms of the
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Available models on improving the uptake of evidence in
policy development only marginally address these factors,
some of which specifically pertain to low-income coun-
tries (LIC) [5,10-12]. Scholars have pointed out the specifi-
city of KT processes, stating that they are influenced by
the nature of the policy, context, and stakeholders in-
volved [12,13].
In the present study, evidence is broadly defined to in-
clude research study results (both published and unpub-
lished), findings from monitoring and evaluation (M&E)
studies and population-based surveys, Ministry of Health
(MoH) reports, community complaints, and clinician ob-
servations [14,15]. The term KT is defined as a dynamic
and iterative process including the synthesis, dissemin-
ation, exchange, and ethically sound application of know-
ledge to improve health, strengthen the healthcare system,
and provide more effective health services and products
[16]. In the present study, the terms “uptake of evi-
dence in policy” and “knowledge translation” are used
interchangeably.
This study, which looks at the uptake of evidence in
policy development, specifically in reference to changes
in the malaria treatment policy and its implementation,
is part of a larger study exploring ways to improve KT in
Uganda. Previous work in Uganda led to the develop-
ment of a middle range theory (MRT) outlining the
main facilitating factors for translating evidence into pol-
icymaking [17]. MRTs are defined here as “theories that
lie between the minor but necessary working hypotheses
(…) and the all-inclusive systematic efforts to develop a
unified theory that will explain all the observed uniform-
ities of social behaviour” [18].
The MRT detailing facilitating factors to the uptake of
evidence as identified by policy actors in Uganda states
the following:
“High-quality and contextualized evidence will be
taken up in policies so as to lead to evidence-informed
policies in instances where the MoH leads the KT
process and there are partnerships for KT in place.
Evidence must be of high quality, contextualized, pro-
viding economically feasible recommendations, and pro-
duced in a timely manner by credible researchers. Use of
local researchers is helpful but there is need for separ-
ation of roles between researchers and policymakers.
KT requires strengthened MoH institutional capacity
to lead the KT process. Institutionalized platforms for
engagement between researchers and policymakers in-
cluding civil society need to be in place, and mecha-
nisms to coordinate evidence generation and synthesis
need to be mainstreamed within the MoH. The capacity
of policy makers in knowledge management needs to bestrengthened and the policy making process need not be
very bureaucratic.
Partnerships for KT need to be in place and all rele-
vant stakeholders must be involved throughout the
process to improve trust and build interest. Communi-
ties need to be involvement in evidence generation and
KT as well.
These contribute to higher ownership, adoption, and
better application of evidence [17]”.
The MRT was developed on the basis of a literature
review and then validated with policy actors in Uganda.
The facilitating factors were collected from respondents
without a specific reference to a given research project
and policy outcome; the extent to which they are valid
in other settings needs to be tested in specific policy case
studies. This study explores the place of evidence in the
design and implementation of the change in malaria
treatment policy in Uganda using a case study approach.
Specifically, the study seeks to assess the extent to which
the previously developed MRT explains the uptake of
evidence in policy development from a policymaking
perspective and explore the barriers and facilitatory fac-
tors to the uptake of evidence in the malaria treatment
policy change. Eventually, the application of this MRT to
concrete, selected health policy cases will contribute to
refining and enriching the previously developed MRT.
Background to the case study
The background to this case study was published by
Nanyunja et al. [19]. The increasing resistance against
chloroquine (CQ) in the late 1990s in several African
countries, as reported by the East African Network on
Monitoring Antimalarial Treatment (EANMAT), caused
concern [20]. EANMAT was established as a platform to
bring together malaria researchers and policy-makers
from the Ministries of Health of the three East African
countries: Kenya, Uganda, and Tanzania. In Uganda, the
MoH set up several sentinel sites in 1997 with support
from EANMAT and the World Health Organization
(WHO) to monitor the efficacy of anti-malarials. The
sentinel sites represented all geographic, epidemiological,
and ecological strata of malaria in Uganda. Evidence
from these sentinel sites showed that resistance to CQ
exceeded the WHO-recommended threshold beyond
which a policy change is recommended [21,22]. Thus,
several countries, including Uganda, embarked on chan-
ging their malaria treatment policies [7,10,19,23,24]. A
review of this process in Uganda highlighted the import-
ance of managing the policy change process, generating
and using evidence for policy decisions, and the avail-
ability of adequate and predictable funding for effective
policy roll-out [19]. The malaria treatment policy initially
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doxine/pyrimethamine (SP) in June 2000. Due to increas-
ing resistance to CQ/SP, the treatment policy was changed
again to artemisinin combination therapy (ACT), specific-
ally artemether-lumefantrine (AL) (trade name Coartem®),
as the first-line treatment for uncomplicated malaria, with
artesunate-amodiaquine (AS/AQ) as an alternative [25].
The process occurred over a period of 25 months, from
March 2004 to April 2006.
Methods
Study design
The case study approach was used based on the need to
understand complex contextual issues [26]. The case is
the malaria treatment policy change from CQ/SP to AL
with AS/AQ as an alternative first-line treatment, which
occurred in Uganda within a time span of 25 months be-
tween March 2004 and April 2006. Case study research
has been shown to offer an opportunity for detailed con-
textual analysis of real life situations when the boundar-
ies between the phenomenon under investigation and
context are not clearly evident [26]. Furthermore, several
researchers have used case studies to test theories in real
life situations [27,28]. The validity of the results was en-
hanced through the use of multiple data collection
methods and member checking [29]. Prior to finalization,
the preliminary results were reviewed by stakeholders who
were central to the policy case: two from the WHO and
two from the MoH. Recall bias was ameliorated by inter-
viewing a wide range of knowledgeable stakeholders andFigure 1 Timeline of key events in changing the malaria treatment poby using multiple data sources [29]. The case study was
performed between June 2012 and August 2013.
In a quest to improve the comprehensiveness and val-
idity of the findings, the present study employed both
qualitative and quantitative methods (QUAL + quant)
which are increasingly being applied to the investigation
of complex issues in health systems research [30,31]. A
timeline of key events was developed based on a review
of documents in consultation with two persons from
the WHO and two persons from the MoH who held
malaria-focused positions for over 10 years. This time-
line guided the identification of key milestones, in-
volved processes, the key documents to be reviewed,
and the institutions involved, which subsequently in-
formed the selection of respondents (Figure 1).
Selection of respondents
The selection of respondents was guided by the study
design. Using the timeline of key events, institutions
were identified that were involved in the policy process.
Key informants (KIs) were selected using purposive sam-
pling, with the main criterion being their involvement in
the research, design, or implementation of the malaria
treatment policy change [32]. From each of the key insti-
tutions, the focal persons involved in the policy change
process were selected and employed the snowballing
technique to identify other key respondents until satur-
ation. Some of the identified respondents had since
moved on to other employment or retired and were cat-
egorized under the institutions they worked for at thelicy.




































&One of the selected districts did not have a private not-for-profit hospital.
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were selected for interviews if they had been involved in
malaria research and provided evidence that was consid-
ered in the policy change process. Emphasis was placed
on collecting their perceptions in line with the study ques-
tions, beyond what they may have published in scientific
papers and research reports.
To obtain perceptions from across the spectrum of the
healthcare delivery system, two districts with high mal-
aria endemicity [33] were purposively selected based on
proximity and the presence of a regional referral hospital
(Jinja district) or general hospital (Mpigi). Within these
districts, two hospitals and two lower level facilities (one
public and one private not-for-profit in both districts)
were purposively selected based on proximity and the
desire to include different levels of the healthcare sys-
tem. At the district level, the district health officer and a
member of the district health team in charge of super-
vising health facilities within the district were purpos-
ively selected. Finally, the medical superintendent, or
health centre employee in charge, and one clinical staff
member responsible for the outpatient department at
each health facility, were purposively selected as these
employees interface with patients on a daily basis and
are more likely to know the malaria burden, community
health-seeking behaviours, and to have interfaced often
with the supervising teams.
The selected respondents included donor representa-
tives, public policy makers, civil society organizations
(CSOs), researchers, the media, and representatives of
the pharmaceutical sector. Managers of health services
at the district level, health care providers from the public
and private not-for-profit health facilities, senior officials
from the national medical stores (NMS) in charge of
medicine procurement and distribution, and managers
from the national drug authority (NDA) in charge of
medicine regulation were also interviewed. Details of the
selected respondents are shown in Table 1.
Selection of relevant documents
The timeline of key events guided the identification of
relevant documents to be reviewed. A broad range of
documents relevant to the case were included in order
to ascertain the processes and stakeholders involved and
assess the use of evidence.
Qualitative research methods
The qualitative part of the study assessed whether evi-
dence was available to guide policy decision-making, the
nature of the evidence that was available, the extent to
which evidence was disseminated and discussed in rele-
vant forums, whether and why evidence had or had not
been considered in policy development and implementa-
tion, and whether policy decisions were in line with theavailable evidence. The barriers and facilitatory factors
to the uptake of evidence in the malaria treatment policy
change and implementation process were explored.
Data collection
Data collection methods included a review of documents
and interviews with KIs. Interviews were conducted with
KIs using an in-depth interview guide consisting of
open-ended questions. The interview guide was devel-
oped by the first author and was reviewed and refined
by the research team prior to pretesting it with volun-
teer colleagues in the WHO Uganda office (n = 2),
technical officers in the MoH (n = 2), and one re-
searcher from the Makerere University School of Pub-
lic Health in Uganda. KIs were contacted and invited
by email or telephone to participate in the study. All
identified respondents accepted to participate and were
interviewed. All interviews were conducted by the first
author face-to-face in English (see Additional file 1).
Relevant documents were reviewed using a review
guideline and included MoH position papers, concept
papers, minutes of meetings, malaria policies and guide-
lines, research reports, malaria proposals to the Global
Fund, reports of working groups, and supervision and
research reports as identified over the timeline of key
events (see Additional files 2 and 3).
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Interviews were recorded, transcribed verbatim, and en-
tered into MS Word software for editing as the first step
in the “formal” analysis. The interviews lasted 45 minutes
on average. During the interviews, the first author made
additional notes of initial findings and impressions, which
were used to enrich the transcribed interviews. Next, the
first author read all of the transcribed interviews to iden-
tify emerging issues, and then the first two authors ana-
lysed the interviews together to identify emerging issues.
Deductive content thematic analysis [34] was used to
organize the emerging issues under themes in line with
the initial MRT. An example of how the deductive contentTable 2 An example of content thematic analysis
Category 1 (manifest)
Evidence used was mainly on the efficacy
of the drugs being used (CQ/SP) and there
was good quality evidence from different
sites in the country showing that the
efficacy of the drugs was declining.
Evidence used was mainly
on the efficacy of the drugs
Good evidence from differen
sites in the country
Though few studies has been done in
Uganda, there were studies in other
countries in the region- Ghana,
Zambia- showing high levels of efficacy
for the ACTs in a similar environment.
The evidence from the clinical studies was
quite good- the studies were comparable
and had been done with adequate sample
sizes. The data were consistently showing
increasing resistance.
High-quality evidence showe
a high level of efficacy for the
ACTs in other similar settings
A lot of international evidence on efficacy
was used, including sentinel surveillance
sites set up by EAMAT, who are respected
professionals.
Evidence from MoH-owned
sentinel studies supported by
respected researchers
There was not overwhelming data in the
country to compare the two (CQ/SP & ACTs);
but real data was available showing
that CQ was failing. Just a few studies
compared ACTs, but the particular ACTs
being used and that were recommended
as the best for the circumstances had only
been investigated by one study in
Uganda.
Real data showing CQ was
failing
There was also the option of taking
amodiaquine artesunate and artemether
lumefantrine. A few studies investigated
artesunate, but studies with amodiaquine
showed that amodiaquine resistance was
not yet at the mark where it cannot be
used, especially if it is in combination with
SP, but the resistance of amodiaquine was
increasing rapidly. Then the issue was that,
if combination therapy is used and
amodiaquine loses efficacy in the next one
to two years, the problem of mono
therapy will return.




As a country, none of the partners
involved in implementing malaria control
activities disagreed with the results on CQ
resistance that came out of the studies.
All partners agreed with
research resultsthematic analysis was conducted is provided in Table 2.
The research team then reviewed and interpreted the find-
ings. Converging issues were reviewed again by the re-
search team and, when interpretations differed, consensus
was achieved by revisiting the raw data and discussions.
Identified regularities were compared with the previously
developed MRT to identify convergent and other emer-
ging issues. Similarities and contrasts between respondent
perceptions were reviewed by the research team and pos-
sible explanations for the contrasting views discussed.
When necessary, quotations that best represent the emer-
ging issues were edited slightly for flow while preserving
the meaning of the text.Category 2 Subtheme Theme
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Quantitative methods were used to capture the multiple
perspectives of the involved stakeholders and enable the
identification of regularities and patterns [35]. The quanti-
tative part of the study measured the frequency with which
evidence was cited in reviewed documents (including dif-
ferent types of evidence) and the respondents’ rating of the
degree of consistency between the policy decision and
available evidence. A policy development framework in-
cluding the steps of agenda setting, policy formulation, se-
lection of preferred options, and implementation [36] was
used to organize the quantitative part of the case study.
Data collection
The document review entailed quantifying the frequency
with which evidence was cited, including the type of evi-
dence (local versus international research; operational re-
search, systematic review, basic research, M & E data).
Using a semi-structured questionnaire, KIs were asked
to rate the consistency between policy decisions and
available evidence. The consistency between evidence and
policy decisions were rated using scales developed by Han-
ney et al. [3], which rate different parameters on a scale of
1 to 4 (1, considerable level of agreement; 2, moderate
level; 3, limited level; 4, no indication of consistency despite
availability of evidence). In applying the scales, the factors
taken into consideration included the degree to which the
policy was consistent with evidence in terms of the defini-
tions of the policy problem and objectives and the descrip-
tion of the strategies and actions, and how far the elements
of the policy contradicted the available evidence.
Data analysis
Quantitative data were analysed using Excel spread-
sheets. Qualitative and quantitative data sets were eventu-
ally triangulated. In addition, findings from the document
analysis and the analysis of KI interviews were integrated
throughout the analysis. Informed consent was obtained
from all respondents prior to the interviews. Study partici-
pants were informed about the purpose of the study and
the scope of issues in the in-depth interview guide. Confi-
dentiality was ensured in data management and only ag-
gregate information without subject identifiers is reported.
All data were secured in a safe location accessible only to
the study team. Ethical approval was obtained from the
Institutional Review Board of the Institute of Tropical
Medicine, Antwerp (Belgium; IRB number IRB/AC/ac/
197) and Uganda National Council for Science and Tech-
nology (number SS 2920).
Results
Use of evidence in changing the malaria treatment policy
The change in malaria treatment policy was reported to
be very technical, and in which the role of evidence wasvery important. A civil society respondent stated more
specifically that, “This is mainly scientific because we are
dealing with technical issues, hence no room for guessing.
As civil society, although we reach out mainly to commu-
nities, we were at task to explain the need for a policy
change using scientific explanations”.
The evidence that was reported to have been available
and considered in the policy process was categorized
into nine areas (Table 3), namely local and international
evidence on drug efficacy, guidance from the WHO,
“cries” from the community, evidence on cost, imple-
mentation feasibility, routine monitoring data, local and
international experiences, observational evidence, and
evidence on behavioural change.
Evidence on the efficacy of CQ/SP and ACT was reviewed,
discussed, and guided decision-making, as highlighted by a
donor respondent: “We used evidence to change the malaria
treatment policy. We mainly used evidence on the efficacy of
the drugs that we were using (CQ/SP). There was good
evidence from different sites in the country showing
that the efficacy of the drugs was really declining”. This
evidence was deemed to be of high quality because multiple
study sites were using a WHO-approved protocol. Technical
support was provided by EANMAT and the WHO when
setting up the sites and for the development of research
protocols, data analysis, and interpretation. Results
from the different sites were consistent, and the results
were consistent with those of other countries with
similar malaria endemicity:
“The methodology to undertake studies on the efficacy
of medicines was thorough, so when we presented the
evidence, there were no loopholes. We made sure that
results were not from only one study area. Otherwise,
with the challenges we had with this malaria
treatment policy shift, if there were loopholes in the
data we would have been shot down, especially at the
point when people started thinking that maybe some
drug companies were the ones pushing it on Uganda
and that the country was not going to afford the new
policy”. (Researcher respondent)
The WHO provided evidence from global and regional
levels, as well as standards with regards to drug resist-
ance cut-off levels at which a country should embark on
changing their malaria treatment policy. This was im-
portant in guiding decision-making, as emphasized in
the following quotes:
“WHO is seen as the authority on clinical matters;
when the WHO takes a stance and says that this drug
is better for patients than the old drug, the country
will often take that recommendation very seriously”.
(Donor respondent)


























Donors 3 3 1 2 1 0 2 1 1
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Central level MoH 7 6 4 1 1
NMS
NDA 1 1 1
Service providers 1 2 2 1 1





Media 1 1 1
Service providers 1 2
Researchers 1 1 1 1 1
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advice and guidance from the WHO. Whenever WHO
updates guidelines or sends out new information, we
take that advice. One of the reasons why a country,
like for example Uganda, should change the policy is
because they are being guided by an international
body like the WHO, which is our technical arm in
policy around malaria and other diseases”. (MoH
respondent)
Cries from the community further created impetus to
take action, as one donor respondent stated, “There was
a public outcry, and the public outcry comes in many
forms, either through newspaper articles or, particularly
if you are the health worker, people will tell you ‘doctor
you gave me this drug for a fever last week and it is not
getting better!’ That is how they communicate to you
their concerns, and that is strong enough. So to me, I
think that is strong enough evidence and we used it”.
At the implementation stage, community complaints,
which referred to perceptions of the effectiveness of Coar-
tem®/AL, were used to address operational challenges:
“When we came in with Coartem, three months later
we started getting complaints from the community
that the new drug was not as effective as CQ; when
you take it you still feel weak and the temperature
does not go down. The problem was not that the new
drug was not working, but it did not have the property
of reducing temperature. So we had to go on radio to
make the announcements nationally saying ‘when you
are taking Coartem®, take an antipyretic like Aspirin
or Panadol together with Coartem,’ and it worked”.
(MoH respondent)
Routine M & E and evidence from supervision reports
were also used at the implementation stage. However,
reservations were expressed by service providers regard-
ing the quality of routine data stating that “we submit
our monthly reports to the District Health office, and
these reports are used in assessing delivery of services,Table 4 Factors that facilitated the uptake of evidence as rep
Donors MoH NMS NDA
p
Characteristics of available evidence 10 20 2
MoH institutional capacity to lead
the KT process
1 8 2
Partnerships for KT 3 7 1
Availability of tools and inputs to
implement evidence
2 5
WHO intervention 3 4including malaria, but I have never seen any change. No
feedback to improve the quality of data”.
Facilitatory factors for the uptake of evidence
Respondents identified factors that facilitated the uptake
of evidence, and these were categorized into five themes:
1) characteristics of the available evidence, 2) MoH insti-
tutional capacity to lead the KT process, 3) partnerships
for KT, 4) availability of tools and inputs to implement
evidence, and 5) intervention of the WHO. These
themes are summarized in Table 4 and the details of
each theme are provided in Additional file 4.
Characteristics of the available evidence
The characteristics of available evidence encompassed
several dimensions, including the availability of high-
quality local evidence, the availability of competent in-
country researchers, consistent results from multiple
studies performed by different researchers, evidence gen-
erated by credible international researchers/regional net-
work, and consensus on research results.
High-quality local evidence on the efficacy of CQ/SP
was available from sentinel sites set up in Uganda by the
MoH with support from EANMAT and the WHO. A
private pharmaceutical representative noted that “the
study design also influenced the uptake of evidence. For
example, they used the WHO tools; people will easily
accept such evidence other than coming up with indi-
vidually designed tools. The WHO tools are already
tested methods”.
Some research studies were performed by competent
in-country researchers who were deemed credible, and
this helped the acceptance of results, as highlighted in
the following quote from a donor respondent:
“Uganda is fortunate that it has a lot of leading
thinkers in malaria who know a lot about malaria.
They were part of the process and were leading in all
the studies. The availability of local data made it
easier for running this case through the different levels
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systems for research”.
International researchers who had generated evidence
from outside the country were also credible, as the MoH
respondent stated, “The regional network EARMAT is
highly respected as a body of senior malaria experts,
their support to sentinel sites in the regions gave a lot of
credibility to the data, and they have been very support-
ive in terms of helping us to understand what is in the
background”.
Consistency in the research results of different study
sites in the country and studies from other East African
countries was a key factor, as stated by a donor respond-
ent, “Evidence sometimes is not easily accepted, but there
was consistency in results from different sites. If you have
several studies from different settings undertaken by dif-
ferent researchers showing the same results, it is easily
accepted”.
Evidence was disseminated through the media, as a
MoH respondent stated, “I remember we had a report
coming out every Monday in the newspapers publicising
the malaria burden”. However, some felt that the extent
to which evidence influenced decision-making could not
be ascertained. A journalist remarked, “We certainly
published a number of stories on drug resistance in the
newspapers although I am not sure to what extent those
publications influenced decisions”.
Similarly, the review of documents pointed to the
availability of contextualized evidence on the efficacy of
anti-malarials from studies performed in the country.
Other sources of high-quality evidence included Demo-
graphic Health Survey (DHS) data supported by Macro
International, the census and national household survey
employing internationally agreed upon methodologies,
and malaria economic studies, which were carried out in
several countries following the WHO protocol.
There was separation of roles, the researchers con-
ducted the studies and policy makers played a leadership
role, receiving and discussing results. Research findings
were discussed in several partnership forums. Evidence
was discussed in the Malaria Case Management Tech-
nical Working Group (MCMWG)a, the Interagency Co-
ordination Committee for Malariab, and the national
stakeholder forum. A research committee was put in place
and included Malaria programme staff, researchers, and
representatives of technical partners (WHO, Malaria Con-
sortium, UNICEF). Research priorities were identified in a
meeting that brought together all relevant stakeholders.
MoH institutional capacity to lead the KT process
The MoH institutional capacity to lead the KT process
encompassed several dimensions, including leadership
role, the willingness of MoH to use evidence, MoHinvolvement in research studies, and a culture of the
MoH using evidence to change treatment policies.
The strong leadership of the MoH and a culture of
using evidence in policy development, facilitated partly
by previous experiences, were echoed by several respon-
dents. A researcher remarked, “I recall that around the
time that we transitioned from CQ/SP to ACT, the NMCP
was in the hands of two people; both of them believed in
evidence”.
There was close collaboration between researchers and
MoH policy makers, as reported by a researcher:
“Our research programme has been working closely
with the MoH and that helps; although were not
always on the same page we had a good relationship.
The sentinel sites were established by the malaria
control programme a long time ago and we are using
them. We have continued that relationship and, when
we do studies, we often discuss with them what we are
going to do and get a go ahead from the ministry. We
have also had funding coming through the Ministry”.
However, one donor respondent expressed reserva-
tions about the quality of MoH participation:
“We have people in the ministry that are not well
versed with the evidence they are using to decide
whether this policy makes sense or not, and therefore
you have people that think they know the evidence but
really they do not”.
The reviewed documents further confirmed that an in-
stitutionalized and systematic data collection system on
drug efficacy was in place through the MoH-established
sentinel sites (established in 1997). In addition, the Health
Management Information System (HMIS), which collects
data on service utilization and malaria cases, was also in
place and managed by the MoH. These sources provided
data that were referenced in the majority of the reviewed
documents.
Furthermore, the MoH commissioned several studies,
including a review of all available data, and closely
followed up with researchers through the implementa-
tion of the research studies. Broad institutionalized plat-
forms were in place for engaging all stakeholders. The
MoH took leadership of the knowledge synthesis and ap-
plication process through participation in, and chairing,
the working group charged with synthesising all available
evidence and making recommendations to the steering
committee, which consisted of the decision-makers.
Partnerships for KT
Partnerships for KT encompassed: the availability of
platforms and structures within the MoH to discuss
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adopted into policy, and civil society involvement.
The availability of structures within the MoH to enable
systematic dialogue was highlighted as a factor that im-
proved the uptake of evidence:
“At that time we had a very good team in the MoH
and the opportunity to discuss things. There were
systems and we had regular meetings and annual
performance reviews. We had quarterly performance
evaluations, which were very important and everyone
had to be there right from the minister, so the climate
for evidence-based decision-making, whether it was
accidental or not, was there in the vision of the
leadership”. (MoH respondent)
Platforms to enable inclusive participation were also
in place for evidence to be discussed, which facilitated
consensus building, as highlighted in the following
quotes:
“The way the policy process worked is that the malaria
programme in the ministry called together all its
technical stakeholders - all its partners - everyone, gov-
ernment, academia, NGOs, etc. Everyone sat in one
room and debated what they thought the best policy
option should be. I thought this was an excellent
process”. (Donor respondent)Figure 2 Partnerships for decision-making.“As a malaria programme, we have what we call a
Malaria Case Management Technical Working Group,
which periodically meets to review how our medicines
are working in the country; so that is another arm
which facilitated the uptake of evidence because we
are able to detect a need for change”. (MoH
respondent)
The document review showed that partnerships were
put in place at several stages of knowledge generation,
synthesis, and application, bringing together relevant
stakeholders. Figure 2 shows partnerships that were put
in place for decision-making, whereas Figure 3 shows
partnerships that were put in place for developing oper-
ation tools and implementing details.
The MCMWG c was put in place to synthesize avail-
able data and make evidence-based recommendations to
the steering committee and MoH. The MCMWG con-
cluded that, “After careful consideration of the evidence
for CQ/SP treatment failure, the meeting agreed that
there was need to change the anti-malarial drug policy
(AMDP). In line with June 2000 recommendations to
adopt a long-term policy and WHO recommendations,
ACT was considered the most viable option to change
to.” A policy decision that conformed to the available
evidence.
Ahead of the national consultative meeting, evidence
on drug resistance against the first-line treatment for
Figure 3 Partnerships for developing operational tools and implementation details.
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was also presented to influential stakeholders in a form
that was easy to understand. A national consultative
stakeholder forum was then held, bringing together re-
searchers, policy makers, clinicians, donors, CSOs, and
district level health managers, and evidence synthesized
by the MCMWG guided the dialogue. The national
stakeholder forum identified information gaps, enabling
all partners to participate in setting the research agenda.
The meeting identified several studies covering several
aspects to provide comprehensive evidence on cost-
effectiveness, acceptability, and the feasibility of imple-
mentation. These studies were then commissioned by
the MoH.
A series of meetings were held ensuring sustained dia-
logue throughout the policy change process. The steer-
ing committee provided regular briefings to members of
MoH top management to apprise them of the situation,
including presentations of synthesized evidence.
After a decision was made to change the first-line
treatment for uncomplicated malaria to AL, the MoH
commissioned task forces that brought together relevant
stakeholders to work out the implementation process
and mainstream implementation of the new policy in
the routine system (Figure 3). In a meeting convened by
the National Drug Authority (NDA), a decision wasmade to ban the importation of CQ and other monother-
apies based on available evidence. The meeting agreed to
strengthen linkages between the NDA, local researchers,
and sentinel sites, to access data in order to prove and
monitor drug efficacy, and to enable policy changes from
time to time.
All stakeholders were represented in the different
working groups and worked together to review the evi-
dence, make policy decisions, and produce operational
tools. All of the task forces were chaired by senior
MoH officials.
Availability of tools and inputs
The provision of guidelines, medicines, and training for
health workers on the new policy are factors that favoured
the implementation of evidence.
A MoH official stated that “some health workers were
totally green about the new anti-malarials; so we devel-
oped training materials and we trained health workers
throughout the country.” A service provider stated that
“the MoH provided us with guidelines which were very
useful when it came to actual implementation of the pol-
icy. The civil society helped us to print more copies of
these guidelines and provide them to health facilities”.
Affordability issues were also raised, despite the avail-
ability of evidence. Some respondents reported that the
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ity of funding from the Global Fund (GF), as highlighted
in the following quotes:
“Around that time, there were was an opening for the
Global Fund, and the possibility of applying for the
Global Fund round 2 to support the policy change was
raised. That was the only way we could realize the
change to the new drug, and when we applied for
funding and got it, that drove the decision”. (MoH
respondent)Table 5 Nature and frequency of evidence cited
Nature of evidence Local evidence& International
Efficacy studiesd 20 10
Monitoring and evaluatione 12
Guidance from WHOf 11







&Refers to evidence from Uganda.
dData on the efficacy of used antimalarials (CQ, SP, amodiaquine). Results from
the Tanzania study and three sentinel sites in Uganda. The Uganda sentinel
sites were put in place and supported by the MoH.
eMainly the Health Management Information System showing malaria burden.
fRecommendation on when to consider changing the first line treatment;
resistance cut-off levels. ACTs are the most effective medicines available to
treat uncomplicated malaria.
gNational household survey data, Uganda poverty participatory assessment
surveys, DHS, census. Citing population-based data on self-reported malaria
cases, use of ITNs, health-seeking behaviour, and access to malaria treatment.
hEvidence of the areas requiring strengthening in the logistic system, health
system weaknesses affecting delivery of malaria interventions, and
implementation experiences on home-based management of fever.
iEvidence of economic burden of malaria, evidence of other malaria control
strategies such as behavioural change issues, and acceptability of the
different anti-malarials.
jClinicians’ observations in Uganda national referral hospitals.“There was the Global Fund at that point, otherwise it
would have taken us a long time to change the
treatment policy if we were to foot it alone. The Global
Fund came on board with rounds where we had to
make proposals to get funding for the new treatment,
and when they gave us funds, we took up the policy”.
(MoH respondent)
The document review showed that the MoH put in
place a mechanism to enable the implementation of evi-
dence; the four task forces shown in Figure 3 were
charged with the responsibility of developing operational
instruments to implement the new policy, including
mainstreaming the implementation of monitoring into
routine systems. The operational tools also incorporated
the evidence.
Barriers to the uptake of evidence
Respondents mentioned resistance from implementers
as one of the barriers that had to be overcome. One
MoH official remarked that “there is a general tendency
of human beings resisting change just by nature, because
they have learned the old ways of giving medicine and
nobody is willing to adjust. So there was a problem with
some of our health workers’ attitude”.
Another reported barrier was the influence of drug
companies, as stated by a service provider, “You know as
part of market dynamics- you will find that once a product
has been in the country for some time, there is a system
which promotes its sale; so when a change is proposed,
there is resistance because someone has been promoting a
product which the company has been selling for some time.
That is one arm that can bar you from adopting good evi-
dence”. Health system considerations and sustainability of
the new policy were among the additional challenges.
Concerns also existed about whether the supply chain sys-
tem would ensure the availability of ACT and whether the
country could sustain the policy from its own resources.
Quantitative results
All 18 of the reviewed documents referenced evidence;
the documents cited evidence 57 times. Each type ofevidence was counted only once in each reviewed docu-
ment. The evidence cited most was mainly locally gener-
ated evidence, as opposed to international, efficacy
studies, M & E, and WHO guidance (Table 5).
Respondents rated the degree of consistency between
the available evidence and decisions at the different
stages of the policy cycle, namely agenda setting, policy
formulation, selection of preferred option, and policy
implementation (Table 6). This rating of the consistence
between evidence and decisions taken was intended to
assess whether evidence played a bigger role at a par-
ticular stage of policy development than at other stages.
The consistency between evidence and decisions was
strongest at the agenda setting stage. Consistency was
moderate in the analytical and decision-making stage
and weak at the implementation stage.
Discussion
Evidence played a key role in changing the malaria treat-
ment policy; however, the level of consistency between
available evidence and decisions varied along the policy
development cycle. The characteristics of the available
evidence, strengthened MoH capacity to lead the KT
process, existence of partnerships for KT, and availability
of tools to implement evidence were the most important
facilitatory factors. Among the barriers to be overcome
Table 6 Respondents’ rating of the consistency between available evidence and policy decisions

















Strong (1) 3 7 1 1 1 2 15




Strong (1) 2 3 1 1 7
Moderate (2) 1 4 1 1 7
Weak (3) 1 1
No influence (4) 1 1
Decision-making
Strong (1) 2 2 1 5
Moderate (2) 1 4 1 1 7
Weak (3) 1 1 1 3
No influence (4) 1 1
Implementation
Strong (1) 2 1 3
Moderate (2) 1 5 1 7
Weak (3) 1 6 5 1 1 1 15
No influence (4) 1 1 2
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capacity to implement the new policy, and financial
sustainability.
The characteristics of the available evidence, as reported
in this study, have been shown to enhance ownership and
the application of evidence [37,38]. In addition, the separ-
ation of roles between researchers and policy makers,
which is an identified factor that can safeguard scientific
rigour and the objectivity of research, was respected
[12,17]. This partly explains the fact that, evidence guided
decision-making. Outcomes have been different in cases
where evidence was deemed to be of poor quality, contra-
dictory, and inconclusive [39]. Mubyazi et al. reported de-
lays in changing the malaria treatment policy because
policy makers casted doubt on the available evidence [7].
Ssengooba et al. reported similar findings for the uptake
of evidence on medical male circumcision as a preventive
measure for HIV; the policy was delayed due to the presi-
dent of the country discrediting research results [9].
The credibility of researchers, receiving support from
the WHO, and utilising regional approaches as opposed
to focusing solely on country efforts are also crucial facili-
tatory factors [40] realized in this study. Similarly, Woelk
et al. documented the intervention of international re-
searchers and involvement of local researchers in regional
and international research networks as a facilitatory factor
to the uptake of evidence in the magnesium sulphate trial
for the treatment of pre-eclampsia [41]. These networksexpose local researchers and clinicians to a culture of
evidence-based decision-making.
Several types of evidence were employed, but the em-
phasis was on the efficacy of medicines. Although the
use of evidence on the efficacy of medicines has been a
common practice in most countries when changing mal-
aria treatment policies, evidence is needed from several
aspects for policy decision-making [10,42]. In some in-
stances, cost considerations and the feasibility of implemen-
tation have driven decision-making despite the availability of
high-quality efficacy data [7]. In addition, community ac-
ceptability has affected the uptake of evidence in some cases.
Malik et al. documented a community preference for drugs
that they knew how to use and were cheap and affordable
[24]. In the case of Uganda, the use of different ACT packs
for different age groups was an identified challenge that af-
fected the implementation of evidence [19]. This finding
highlights the need for comprehensive evidence to guide
decision-making and, in this study, evidence was available
on health seeking behaviour, access to anti-malarials, the
capacity of the supply chain system, community acceptabil-
ity of anti-malarial interventions, the affordability of the new
policy by the government, and the capacity of the health sys-
tem to implement the changes.
The tailored dissemination to influential stakeholders,
which occurred at the beginning of the policy process,
could have influenced decision-making, as evidenced by
the strong rating of the influence of evidence on decisions
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of evidence has been documented as a facilitatory factor
to the uptake of evidence [43,44]. However, the reduced
consistency noted when moving from the analytical stage
to implementation may not solely be the result of the dis-
semination modalities used; it may imply that other fac-
tors played a more central role than evidence. These are
stages where issues such as affordability, health system
issues, political will, and donor interest have influ-
enced debates [45].
KT has been realized in instances where the MoH has
the capacity to take a leadership role in coordinating the
generation, synthesis, and application of evidence [46,47],
which was the case in this study. In their study of six
countries in Southern Africa, Varkevisser et al. docu-
mented the successful uptake of evidence into policy
where ministries of health led the process of evidence syn-
thesis and dissemination [46]. In contrast, Lavis et al.
documented successful KT when structures outside
the ministries of health led the evidence synthesis and
dissemination process, but these were in areas of clin-
ical care and technology assessment [48]. In this case
study, a two pronged approach was employed with
mainstream structures, which have been shown to be
beneficial given the opportunity to engage with stake-
holders more effectively [47], and regional professional
bodies, which have been shown to be very effective, espe-
cially for getting evidence into clinical practice [14,48].
Some scholars have argued that mainstream structures are
more relevant for getting evidence into public health pol-
icies [47], but these may also play a role in getting evi-
dence into clinical practice, more so in low income
countries where clinical decisions have far reaching
health system implications. The presence of institu-
tionalized platforms for KT, as existed in this case
study, have been shown to be beneficial [3]. Ssengooba
et al. also documented successful KT in Uganda where
the uptake of evidence on the prevention of mother to
child transmission was facilitated by the presence of
KT platforms [9]. A long history of partnerships, as
seen in this case study, helped build trust over the
years and created a platform from which evidence
could be discussed and decisions made. The involve-
ment of relevant stakeholders in partnerships throughout
the process, from knowledge generation to applications,
was shown to enhance the uptake of evidence in policy
development [17,24]. Colon et al. documented a case in
which the application of evidence was frustrated by weak
partnerships engulfed in suspicions and protection of per-
sonal interests [49]. Although partnerships are beneficial,
the realization of positive results in not always obvious,
and among documented challenges is the varied cap-
acity of stakeholders [40], effective leadership to en-
courage open dialogue and ensure respect [50], andtime constraints on the part of decision-makers to
allow the mobilization and participation of stakeholders.
In this case study, these issues could have been amelio-
rated two ways. First, partnerships in policy making re-
garding malaria issues was a long-standing tradition.
Second, partnerships in health policy development in
general were already ingrained in the vision of the
leadership, with participation at the highest level of the
MoH.
Communities have been shown to be key stakeholders
and, in this study, “community cries” created an impetus
for policy change. Although effective community en-
gagement remains a challenge in several low-income set-
tings due to a lack of structures and resources [51], they
are stakeholders in KT whose role could be maximized.
The need for targeted dissemination to communities has
been raised following the argument that, if they are
armed with the right information, they can demand that
certain policies be put in place [1,52]. In this case study,
the media played a role in disseminating evidence through
newspapers, and this could have facilitated community
involvement.
In this study, the provision of guidelines and medi-
cines, training health workers on the new policy, and
mainstreaming the implementation in routine processes
favoured the implementation of evidence. Scholars have
documented failed KT in several low income settings
due to a lack of medicines, drug licensing, inadequate
human resources, and lack of training [6,7,51,53]. Kang-
wana et al. also documented challenges to implementing
the revised malaria treatment policy due to a lack of
ACTs [54], whereas Bergstrom et al. documented the
failure of health workers to implement new knowledge
due to a lack of required medicines and equipment [55].
Instances exist in which the affordability was the major
factor guiding decision-making despite the availability of
efficacy data, such as the case of changing the anti-
malarial treatment policy in Tanzania [7]. This was also
a key consideration in this case study as highlighted
that … there was the Global Fund at that point otherwise
it would have taken us a long time to change the treatment
policy. Donor funding requirements have also influenced
decision-making in other settings, such as the develop-
ment of HIV care guidelines in Ghana [45].
The present results agree with the facilitatory factors
identified in the earlier developed MRT on KT in Uganda,
although additional factors and themes also emerged. The
MRT was refined as follows:
High-quality and contextualized evidence will be
taken up in policies so as to lead to evidence-informed
policies in instances where the MoH leads the KT
process, the WHO and regional professional bodies
play a role, partnerships for KT, and tools and
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evidence.
Evidence must be of high quality, contextualized, pro-
vide economically feasible recommendations, and pro-
duced in a timely manner by credible researchers. Use of
local researchers is helpful but there is a need for the
separation of roles between researchers and policy-
makers. Effective dissemination of evidence to communi-
ties and tailored dissemination to influential stakeholders
is also needed.
KT requires strengthened MoH institutional capacity
to lead the KT process. Institutionalized platforms for
engagement between researchers and policymakers, in-
cluding civil society, need to be in place. Mechanisms to
coordinate evidence generation and synthesis need to be
mainstreamed within the MoH, although regional pro-
fessional bodies also play a role and the WHO’s inter-
vention is helpful. The capacity of policy makers in
knowledge management needs to be strengthened and
the policy making process must not be very bureaucratic.
Partnerships for KT need to be in place, and all rele-
vant stakeholders must be involved throughout the
process to improve trust and build interest. Building a
culture of partnerships in health development over time
enhances trust. Communities need to be involved in evi-
dence generation and translation.
The availability of funding, tools, and inputs to imple-
ment evidence is crucial. Funding must be available, oper-
ational tools must be provided, and implementers must
receive required training to implement the evidence.
These contribute to higher ownership, adoption, and
better application of evidence.Strengths and weakness
The strengths of this study are the use of multiple data
sources and interviews with a wide range of respondents,
which generated a rich data set from which to assess the
use of evidence. Among the weaknesses of this study is
potential recall bias; interviews were conducted long
after the policy development process occurred. However,
the recall bias was ameliorated by the use of multiple
sources of data. Rating has been attempted for the de-
gree of consistency between available evidence and the
decisions made at the different stages of policy develop-
ment, but in reality the stages are not that distinct. The
policy process is iterative.
Conclusion
Different types of evidence were used in changing the
malaria treatment policy in Uganda, though the level of
consistency between evidence and policy decisions variedalong the policy development cycle. Respondents per-
ceived the availability of high-quality and contextualized
evidence, including targeted dissemination of evidence to
communities and influential stakeholders; MoH institu-
tional capacity to lead the KT process; the intervention of
the WHO and a regional professional network in evidence
generation and policy development; existence of partner-
ships for KT with mutual trust; and the availability of
funding, tools, and inputs to implement evidence as the
most important facilitatory factors that enhanced the up-
take of evidence in the malaria treatment policy change.
Context is very important in KT, and the refined MRT
may not hold in all contexts, but it can serve as a starting
point for other countries planning to embark on changing
their malaria treatment policies and seeking to maximize
the use of evidence.
Endnotes
aThis was charged with spearheading all technical as-
pects of the change in the malaria treatment policy.
bThis committee provided oversight over the work of
the Malaria Case Management Technical Working Group.
cTechnical committee - Malaria Case Management
Technical Working Group (MCMWG) put in place to
synthesize available data (technical committee) and make
evidence-based recommendations to the steering commit-
tee and MoH. Malaria Case Management Group com-
prised the MoH (UNMCP, planning, pharmacy, HMIS,
ESD), WHO, NDA, NMS, JMS, DHO, hospitals, CSO,
public health lab, researchers, UNICEF, and MoF.
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